Psychometric evaluation of ADAS-Cog and NTB for measuring drug response
Aims To conduct a psychometric analysis to determine the adequacy of instruments that measure cognition in Alzheimer's disease trials. Background Both the Alzheimer's Disease Assessment Scale ‐ Cognition (ADAS‐Cog) and the Neuropsychological Test Battery (NTB) are validated outcome measure...
Gespeichert in:
| Veröffentlicht in: | Acta neurologica Scandinavica 2014-02, Vol.129 (2), p.114-122 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 122 |
|---|---|
| container_issue | 2 |
| container_start_page | 114 |
| container_title | Acta neurologica Scandinavica |
| container_volume | 129 |
| creator | Karin, A. Hannesdottir, K. Jaeger, J. Annas, P. Segerdahl, M. Karlsson, P. Sjögren, N. von Rosen, T. Miller, F. |
| description | Aims
To conduct a psychometric analysis to determine the adequacy of instruments that measure cognition in Alzheimer's disease trials.
Background
Both the Alzheimer's Disease Assessment Scale ‐ Cognition (ADAS‐Cog) and the Neuropsychological Test Battery (NTB) are validated outcome measures for clinical trials in Alzheimer's disease and are approved also for regulatory purposes. However, it is not clear how comparable they are in measuring cognitive function. In fact, many recent trials in Alzheimer's disease patients have failed and it has been questioned if ADAS‐Cog still is a sensitive measure.
Materials and Methods
The present paper examines the psychometric properties of ADAS‐Cog and NTB, based on a post hoc analysis of data from a clinical trial (NCT01024660), which was conducted by AstraZeneca, in mild‐to‐moderate Alzheimer's disease (AD) patients, with a Mini Mental State Examination (MMSE) Total score 16‐24. Acceptability, reliability, different types of validity and ability to detect change were assessed using relevant statistical methods. Total scores of both tests, as well as separate domains of both tests, including the Wechsler Memory Scale (WMS), Rey Auditory Verbal Learning Test (RAVLT) and Delis‐Kaplan Executive Function System (D‐KEFS) Verbal Fluency Condition, were analyzed.
Results
Overall, NTB performed well, with acceptable reliability and ability to detect change, while ADAS‐Cog had insufficient psychometric properties, including ceiling effects in 8 out of a total of 11 ADAS‐Cog items in mild AD patients, as well as low test‐retest reliability in some of the items.
Discussion
Based on a direct comparison on the same patient sample, we see advantages of the NTB compared with the ADAS‐Cog for the evaluation of cognitive function in the population of mild‐to‐moderate AD patients. The results suggest that not all of ADAS‐Cog items are relevant for both mild and moderate AD population.
Conclusions
This validation study demonstrates satisfactory psychometric properties of the NTB, while ADAS‐Cog was found to be psychometrically inadequate. |
| doi_str_mv | 10.1111/ane.12153 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_528834</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1490707820</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5333-88d3280b9908fe64fa8cdd9ee66c97195982dc5c9ac49d8433a1b49d4c73a9693</originalsourceid><addsrcrecordid>eNqN0U1v0zAYB3ALgVgZHPgCKBKXIZTNjt-PabsFpKmAGHC0XMcp3pK42DVbvz0e7XpAmoQvftHPfz16HgBeI3iK8jrToz1FFaL4CZggBmEJCSRPwQRCiEqGETkCL2K8zreKE_IcHFWYM0wonIDmc9yan36wm-BMYX_rPumN82Phu6Ke11_LmV8VemyLxdW06HwoBqtjCm5cFW1IqyLYuPZjtC_Bs0730b7a78fg28X51exDefmp-TirL0tDMcalEC2uBFxKCUVnGem0MG0rrWXMSI4klaJqDTVSGyJbQTDWaJlPxHCsJZP4GJS73Hhr12mp1sENOmyV107tn27yySpaCYFJ9u8f9XP3vVY-rFRMSlIIRdYnO70O_leycaMGF43t-9xhn6JCRDIhKEfwfyjkkIvqnr79h177FMbcpqw4xTyXSrN6t1Mm-BiD7Q61Iqjux6xysvo75mzf7BPTcrDtQT7MNYOzHbh1vd0-nqTqxflD5L6xLm7s3eGHDjeKccyp-rFo1JSIL_NmSlSD_wCKir24</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1475372885</pqid></control><display><type>article</type><title>Psychometric evaluation of ADAS-Cog and NTB for measuring drug response</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>SWEPUB Freely available online</source><creator>Karin, A. ; Hannesdottir, K. ; Jaeger, J. ; Annas, P. ; Segerdahl, M. ; Karlsson, P. ; Sjögren, N. ; von Rosen, T. ; Miller, F.</creator><creatorcontrib>Karin, A. ; Hannesdottir, K. ; Jaeger, J. ; Annas, P. ; Segerdahl, M. ; Karlsson, P. ; Sjögren, N. ; von Rosen, T. ; Miller, F.</creatorcontrib><description>Aims
To conduct a psychometric analysis to determine the adequacy of instruments that measure cognition in Alzheimer's disease trials.
Background
Both the Alzheimer's Disease Assessment Scale ‐ Cognition (ADAS‐Cog) and the Neuropsychological Test Battery (NTB) are validated outcome measures for clinical trials in Alzheimer's disease and are approved also for regulatory purposes. However, it is not clear how comparable they are in measuring cognitive function. In fact, many recent trials in Alzheimer's disease patients have failed and it has been questioned if ADAS‐Cog still is a sensitive measure.
Materials and Methods
The present paper examines the psychometric properties of ADAS‐Cog and NTB, based on a post hoc analysis of data from a clinical trial (NCT01024660), which was conducted by AstraZeneca, in mild‐to‐moderate Alzheimer's disease (AD) patients, with a Mini Mental State Examination (MMSE) Total score 16‐24. Acceptability, reliability, different types of validity and ability to detect change were assessed using relevant statistical methods. Total scores of both tests, as well as separate domains of both tests, including the Wechsler Memory Scale (WMS), Rey Auditory Verbal Learning Test (RAVLT) and Delis‐Kaplan Executive Function System (D‐KEFS) Verbal Fluency Condition, were analyzed.
Results
Overall, NTB performed well, with acceptable reliability and ability to detect change, while ADAS‐Cog had insufficient psychometric properties, including ceiling effects in 8 out of a total of 11 ADAS‐Cog items in mild AD patients, as well as low test‐retest reliability in some of the items.
Discussion
Based on a direct comparison on the same patient sample, we see advantages of the NTB compared with the ADAS‐Cog for the evaluation of cognitive function in the population of mild‐to‐moderate AD patients. The results suggest that not all of ADAS‐Cog items are relevant for both mild and moderate AD population.
Conclusions
This validation study demonstrates satisfactory psychometric properties of the NTB, while ADAS‐Cog was found to be psychometrically inadequate.</description><identifier>ISSN: 0001-6314</identifier><identifier>ISSN: 1600-0404</identifier><identifier>EISSN: 1600-0404</identifier><identifier>DOI: 10.1111/ane.12153</identifier><identifier>PMID: 23763450</identifier><identifier>CODEN: ANRSAS</identifier><language>eng</language><publisher>Denmark: Blackwell Publishing Ltd</publisher><subject>acceptability ; Aged ; Aged, 80 and over ; Alzheimer Disease - diagnosis ; Alzheimer Disease - drug therapy ; Alzheimer's disease ; Alzheimer's Disease Assessment Scale-Cog ; ceiling effects ; Cognition & reasoning ; Cognition - drug effects ; cognitive testing ; Female ; Humans ; Indans - therapeutic use ; Male ; Middle Aged ; neurologi ; Neurology ; neuropsychological test battery ; Neuropsychological Tests ; Nootropic Agents - therapeutic use ; Older people ; Piperidines - therapeutic use ; Psychology ; psychometric properties ; Psychometrics ; psykologi ; Randomized Controlled Trials as Topic ; Statistical methods ; Statistics ; statistik ; validation</subject><ispartof>Acta neurologica Scandinavica, 2014-02, Vol.129 (2), p.114-122</ispartof><rights>2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>Copyright © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5333-88d3280b9908fe64fa8cdd9ee66c97195982dc5c9ac49d8433a1b49d4c73a9693</citedby><cites>FETCH-LOGICAL-c5333-88d3280b9908fe64fa8cdd9ee66c97195982dc5c9ac49d8433a1b49d4c73a9693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fane.12153$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fane.12153$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,552,778,782,883,1414,27911,27912,45561,45562</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23763450$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-95008$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:128055787$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Karin, A.</creatorcontrib><creatorcontrib>Hannesdottir, K.</creatorcontrib><creatorcontrib>Jaeger, J.</creatorcontrib><creatorcontrib>Annas, P.</creatorcontrib><creatorcontrib>Segerdahl, M.</creatorcontrib><creatorcontrib>Karlsson, P.</creatorcontrib><creatorcontrib>Sjögren, N.</creatorcontrib><creatorcontrib>von Rosen, T.</creatorcontrib><creatorcontrib>Miller, F.</creatorcontrib><title>Psychometric evaluation of ADAS-Cog and NTB for measuring drug response</title><title>Acta neurologica Scandinavica</title><addtitle>Acta Neurol Scand</addtitle><description>Aims
To conduct a psychometric analysis to determine the adequacy of instruments that measure cognition in Alzheimer's disease trials.
Background
Both the Alzheimer's Disease Assessment Scale ‐ Cognition (ADAS‐Cog) and the Neuropsychological Test Battery (NTB) are validated outcome measures for clinical trials in Alzheimer's disease and are approved also for regulatory purposes. However, it is not clear how comparable they are in measuring cognitive function. In fact, many recent trials in Alzheimer's disease patients have failed and it has been questioned if ADAS‐Cog still is a sensitive measure.
Materials and Methods
The present paper examines the psychometric properties of ADAS‐Cog and NTB, based on a post hoc analysis of data from a clinical trial (NCT01024660), which was conducted by AstraZeneca, in mild‐to‐moderate Alzheimer's disease (AD) patients, with a Mini Mental State Examination (MMSE) Total score 16‐24. Acceptability, reliability, different types of validity and ability to detect change were assessed using relevant statistical methods. Total scores of both tests, as well as separate domains of both tests, including the Wechsler Memory Scale (WMS), Rey Auditory Verbal Learning Test (RAVLT) and Delis‐Kaplan Executive Function System (D‐KEFS) Verbal Fluency Condition, were analyzed.
Results
Overall, NTB performed well, with acceptable reliability and ability to detect change, while ADAS‐Cog had insufficient psychometric properties, including ceiling effects in 8 out of a total of 11 ADAS‐Cog items in mild AD patients, as well as low test‐retest reliability in some of the items.
Discussion
Based on a direct comparison on the same patient sample, we see advantages of the NTB compared with the ADAS‐Cog for the evaluation of cognitive function in the population of mild‐to‐moderate AD patients. The results suggest that not all of ADAS‐Cog items are relevant for both mild and moderate AD population.
Conclusions
This validation study demonstrates satisfactory psychometric properties of the NTB, while ADAS‐Cog was found to be psychometrically inadequate.</description><subject>acceptability</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alzheimer Disease - diagnosis</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer's disease</subject><subject>Alzheimer's Disease Assessment Scale-Cog</subject><subject>ceiling effects</subject><subject>Cognition & reasoning</subject><subject>Cognition - drug effects</subject><subject>cognitive testing</subject><subject>Female</subject><subject>Humans</subject><subject>Indans - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>neurologi</subject><subject>Neurology</subject><subject>neuropsychological test battery</subject><subject>Neuropsychological Tests</subject><subject>Nootropic Agents - therapeutic use</subject><subject>Older people</subject><subject>Piperidines - therapeutic use</subject><subject>Psychology</subject><subject>psychometric properties</subject><subject>Psychometrics</subject><subject>psykologi</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Statistical methods</subject><subject>Statistics</subject><subject>statistik</subject><subject>validation</subject><issn>0001-6314</issn><issn>1600-0404</issn><issn>1600-0404</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>D8T</sourceid><recordid>eNqN0U1v0zAYB3ALgVgZHPgCKBKXIZTNjt-PabsFpKmAGHC0XMcp3pK42DVbvz0e7XpAmoQvftHPfz16HgBeI3iK8jrToz1FFaL4CZggBmEJCSRPwQRCiEqGETkCL2K8zreKE_IcHFWYM0wonIDmc9yan36wm-BMYX_rPumN82Phu6Ke11_LmV8VemyLxdW06HwoBqtjCm5cFW1IqyLYuPZjtC_Bs0730b7a78fg28X51exDefmp-TirL0tDMcalEC2uBFxKCUVnGem0MG0rrWXMSI4klaJqDTVSGyJbQTDWaJlPxHCsJZP4GJS73Hhr12mp1sENOmyV107tn27yySpaCYFJ9u8f9XP3vVY-rFRMSlIIRdYnO70O_leycaMGF43t-9xhn6JCRDIhKEfwfyjkkIvqnr79h177FMbcpqw4xTyXSrN6t1Mm-BiD7Q61Iqjux6xysvo75mzf7BPTcrDtQT7MNYOzHbh1vd0-nqTqxflD5L6xLm7s3eGHDjeKccyp-rFo1JSIL_NmSlSD_wCKir24</recordid><startdate>201402</startdate><enddate>201402</enddate><creator>Karin, A.</creator><creator>Hannesdottir, K.</creator><creator>Jaeger, J.</creator><creator>Annas, P.</creator><creator>Segerdahl, M.</creator><creator>Karlsson, P.</creator><creator>Sjögren, N.</creator><creator>von Rosen, T.</creator><creator>Miller, F.</creator><general>Blackwell Publishing Ltd</general><general>Hindawi Limited</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>DG7</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>201402</creationdate><title>Psychometric evaluation of ADAS-Cog and NTB for measuring drug response</title><author>Karin, A. ; Hannesdottir, K. ; Jaeger, J. ; Annas, P. ; Segerdahl, M. ; Karlsson, P. ; Sjögren, N. ; von Rosen, T. ; Miller, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5333-88d3280b9908fe64fa8cdd9ee66c97195982dc5c9ac49d8433a1b49d4c73a9693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>acceptability</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alzheimer Disease - diagnosis</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer's disease</topic><topic>Alzheimer's Disease Assessment Scale-Cog</topic><topic>ceiling effects</topic><topic>Cognition & reasoning</topic><topic>Cognition - drug effects</topic><topic>cognitive testing</topic><topic>Female</topic><topic>Humans</topic><topic>Indans - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>neurologi</topic><topic>Neurology</topic><topic>neuropsychological test battery</topic><topic>Neuropsychological Tests</topic><topic>Nootropic Agents - therapeutic use</topic><topic>Older people</topic><topic>Piperidines - therapeutic use</topic><topic>Psychology</topic><topic>psychometric properties</topic><topic>Psychometrics</topic><topic>psykologi</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Statistical methods</topic><topic>Statistics</topic><topic>statistik</topic><topic>validation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karin, A.</creatorcontrib><creatorcontrib>Hannesdottir, K.</creatorcontrib><creatorcontrib>Jaeger, J.</creatorcontrib><creatorcontrib>Annas, P.</creatorcontrib><creatorcontrib>Segerdahl, M.</creatorcontrib><creatorcontrib>Karlsson, P.</creatorcontrib><creatorcontrib>Sjögren, N.</creatorcontrib><creatorcontrib>von Rosen, T.</creatorcontrib><creatorcontrib>Miller, F.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Stockholms universitet</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>Acta neurologica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karin, A.</au><au>Hannesdottir, K.</au><au>Jaeger, J.</au><au>Annas, P.</au><au>Segerdahl, M.</au><au>Karlsson, P.</au><au>Sjögren, N.</au><au>von Rosen, T.</au><au>Miller, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psychometric evaluation of ADAS-Cog and NTB for measuring drug response</atitle><jtitle>Acta neurologica Scandinavica</jtitle><addtitle>Acta Neurol Scand</addtitle><date>2014-02</date><risdate>2014</risdate><volume>129</volume><issue>2</issue><spage>114</spage><epage>122</epage><pages>114-122</pages><issn>0001-6314</issn><issn>1600-0404</issn><eissn>1600-0404</eissn><coden>ANRSAS</coden><abstract>Aims
To conduct a psychometric analysis to determine the adequacy of instruments that measure cognition in Alzheimer's disease trials.
Background
Both the Alzheimer's Disease Assessment Scale ‐ Cognition (ADAS‐Cog) and the Neuropsychological Test Battery (NTB) are validated outcome measures for clinical trials in Alzheimer's disease and are approved also for regulatory purposes. However, it is not clear how comparable they are in measuring cognitive function. In fact, many recent trials in Alzheimer's disease patients have failed and it has been questioned if ADAS‐Cog still is a sensitive measure.
Materials and Methods
The present paper examines the psychometric properties of ADAS‐Cog and NTB, based on a post hoc analysis of data from a clinical trial (NCT01024660), which was conducted by AstraZeneca, in mild‐to‐moderate Alzheimer's disease (AD) patients, with a Mini Mental State Examination (MMSE) Total score 16‐24. Acceptability, reliability, different types of validity and ability to detect change were assessed using relevant statistical methods. Total scores of both tests, as well as separate domains of both tests, including the Wechsler Memory Scale (WMS), Rey Auditory Verbal Learning Test (RAVLT) and Delis‐Kaplan Executive Function System (D‐KEFS) Verbal Fluency Condition, were analyzed.
Results
Overall, NTB performed well, with acceptable reliability and ability to detect change, while ADAS‐Cog had insufficient psychometric properties, including ceiling effects in 8 out of a total of 11 ADAS‐Cog items in mild AD patients, as well as low test‐retest reliability in some of the items.
Discussion
Based on a direct comparison on the same patient sample, we see advantages of the NTB compared with the ADAS‐Cog for the evaluation of cognitive function in the population of mild‐to‐moderate AD patients. The results suggest that not all of ADAS‐Cog items are relevant for both mild and moderate AD population.
Conclusions
This validation study demonstrates satisfactory psychometric properties of the NTB, while ADAS‐Cog was found to be psychometrically inadequate.</abstract><cop>Denmark</cop><pub>Blackwell Publishing Ltd</pub><pmid>23763450</pmid><doi>10.1111/ane.12153</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-6314 |
| ispartof | Acta neurologica Scandinavica, 2014-02, Vol.129 (2), p.114-122 |
| issn | 0001-6314 1600-0404 1600-0404 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_528834 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; SWEPUB Freely available online |
| subjects | acceptability Aged Aged, 80 and over Alzheimer Disease - diagnosis Alzheimer Disease - drug therapy Alzheimer's disease Alzheimer's Disease Assessment Scale-Cog ceiling effects Cognition & reasoning Cognition - drug effects cognitive testing Female Humans Indans - therapeutic use Male Middle Aged neurologi Neurology neuropsychological test battery Neuropsychological Tests Nootropic Agents - therapeutic use Older people Piperidines - therapeutic use Psychology psychometric properties Psychometrics psykologi Randomized Controlled Trials as Topic Statistical methods Statistics statistik validation |
| title | Psychometric evaluation of ADAS-Cog and NTB for measuring drug response |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T10%3A29%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psychometric%20evaluation%20of%20ADAS-Cog%20and%20NTB%20for%20measuring%20drug%20response&rft.jtitle=Acta%20neurologica%20Scandinavica&rft.au=Karin,%20A.&rft.date=2014-02&rft.volume=129&rft.issue=2&rft.spage=114&rft.epage=122&rft.pages=114-122&rft.issn=0001-6314&rft.eissn=1600-0404&rft.coden=ANRSAS&rft_id=info:doi/10.1111/ane.12153&rft_dat=%3Cproquest_swepu%3E1490707820%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1475372885&rft_id=info:pmid/23763450&rfr_iscdi=true |